Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease

Archives of Neurology

Volumn 62, Issue 12, 2005, Pages 1833-1837

  Stover, Natividad P ^a   Bakay, Roy A E ^b   Subramanian, Thyagarajan ^c   Raiser, Cathy D ^d   Cornfeldt, Michael L ^e   Schweikert, Alfred W ^e   Allen, Richard C ^e   Watts, Ray L ^a  

^a The University of Alabama at Birmingham   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Titan Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; EVALUATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEDICAL PRACTICE; MONKEY; PARKINSON DISEASE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PUTAMEN; QUALITY OF LIFE; RODENT;

ANTIPARKINSON AGENTS; CELLS, CULTURED; CEREBRAL HEMORRHAGE; CORPUS STRIATUM; DEPRESSIVE DISORDER; GELATIN; GRAFT SURVIVAL; HUMANS; LEVODOPA; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PARKINSON DISEASE; PIGMENT EPITHELIUM OF EYE; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PUTAMEN; RECOVERY OF FUNCTION; STEREOTAXIC TECHNIQUES; TREATMENT OUTCOME;

EID: 28944447738     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.12.1833     Document Type: Article

References (19)

1. Rajput AH. Clinical features and natural history of Parkinson's disease (special consideration of aging). In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia, Pa: WB Saunders Co; 1994:555-572.
2. Wainer BH, Stover NP. Parkinson's disease: neuropathology. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice. 2nd ed. New York, NY: McGraw-Hill; 2004:327-336.
3. Poewe W, Granata R, Geser F. Pharmacologic treatment of Parkinson's disease. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice. 2nd ed. New York, NY: McGraw-Hill; 2004:247-271.
4. MouradianMM,Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol. 1987;22:475-479.
5. Subramanian T. Cell transplantation for the treatment of Parkinson's disease. Semin Neurol. 2001;21:103-115.
6. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344:710-719.
7. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54:403-414.
8. Boulton M. Melanin and the retinal pigment epithelium. In: Marmor MF, Wolfensberger TJ, eds. The Retinal Pigment Epithelium: Function and Disease. New York, NY: Oxford University Press; 1998:68-85.
9. Pfeffer BA. Improved methodology for cell culture of human and monkey retinal pigment epithelium. In: Osborne NN, Chader G, eds. Progress in Retinal Research. Vol 10. Oxford, England: Pergamon Press; 1990:251-291.
10. Tezel TH, Del Priore VL. Reattachment to a substrate prevents apoptosis of human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol. 1997;235:41-47.
11. Cherksey BD,inventor; Titan Pharmaceuticals Inc, assignee. Method of increasing viability of cells which are administered to the brain or spinal cord. US patent 5 618 531. April 8, 1997.
12. Watts RL, Raiser CD, Stover NP, et al. Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. J Neural Transm Suppl. 2003;65:215-227.
13. Subramanian T, Marchionini D, Potter EM, Cornfeldt ML. Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant. 2002;11:207-214.
14. Hauser RA, Driedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesias. Clin Neuropharmacol. 2000;23:75-81.
15. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord. 1994;9:390-394.
16. Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995;4:241-248.
17. Deep Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345:956-963.
18. Shetty N, Friedman JH, Kieburtz K, et al. The placebo response in Parkinson's disease. Clin Neuropharmacol. 1999;22:207-212.
19. Goetz CG, Leurgans S, Raman R, et al. Objective changes in motor function during placebo treatment in Parkinson's disease. Neurology. 2000;54:710-714.